Citations for
1CDCA7, DNMT3B, HELLS, ICF1, ICF2, ICF3, ICF4, ZBTB24
CDCA7 and HELLS mutations undermine nonhomologous end joining in centromeric instability syndrome.
Unoki M, Funabiki H, Velasco G, Francastel C, Sasaki H.
J Clin Invest 129(1):78-92. doi: 10.1172/JCI99751. Epub 2018 Nov 19. 2019
2CDCA7, DNMT3B, HELLS, ICF1, ICF2, ICF3, ICF4, ZBTB24
Three Types of Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome Identified by Whole-Exome Sequencing in Saudi Hypogammaglobulinemia Patients: Clinical, Molecular, and Cytogenetic Features.
Alghamdi HA, Tashkandi SA, Alidrissi EM, Aledielah RD, AlSaidi KA, Alharbi ES, Habazi MK, Alzahrani MS.
J Clin Immunol 38(8):847-853. doi: 10.1007/s10875-018-0569-9. Epub 2018 Dec 3. No abstract available. 2018
3CDCA7, HELLS, ICF2, ICF3, ICF4, ZBTB24
Comparative methylome analysis of ICF patients identifies heterochromatin loci that require ZBTB24, CDCA7 and HELLS for their methylated state.
Velasco G, Grillo G, Touleimat N, Ferry L, Ivkovic I, Ribierre F, Deleuze JF, Chantalat S, Picard C, Francastel C.
Hum Mol Genet 27(14):2409-2424. doi: 10.1093/hmg/ddy130. 2018
4CDCA7, HELLS
HELLS and CDCA7 comprise a bipartite nucleosome remodeling complex defective in ICF syndrome.
Jenness C, Giunta S, Müller MM, Kimura H, Muir TW, Funabiki H.
Proc Natl Acad Sci U S A 115(5):E876-E885. doi: 10.1073/pnas.1717509115. Epub 2018 Jan 16. 2018
5CDCA7, ZBTB24
Converging disease genes in ICF syndrome: ZBTB24 controls expression of CDCA7 in mammals.
Wu H, Thijssen PE, de Klerk E, Vonk KK, Wang J, den Hamer B, Aytekin C, van der Maarel SM, Daxinger L.
Hum Mol Genet 25(18):4041-4051. doi: 10.1093/hmg/ddw243. Epub 2016 Jul 27. 2016
6CDCA7, HELLS, ICF3, ICF4
Mutations in CDCA7 and HELLS cause immunodeficiency-centromeric instability-facial anomalies syndrome.
Thijssen PE, Ito Y, Grillo G, Wang J, Velasco G, Nitta H, Unoki M, Yoshihara M, Suyama M, Sun Y, Lemmers RJ, de Greef JC, Gennery A, Picco P, Kloeckener-Gruissem B, Güngör T, Reisli I, Picard C, Kebaili K, Roquelaure B, Iwai T, Kondo I, Kubota T, van Ostaijen-Ten Dam MM, van Tol MJ, Weemaes C, Francastel C, van der Maarel SM, Sasaki H.
Nat Commun 6:7870. doi: 10.1038/ncomms8870. 2015
7CDCA7
Identification of Cdca7 as a novel Notch transcriptional target involved in hematopoietic stem cell emergence.
Guiu J, Bergen DJ, De Pater E, Islam AB, Ayllón V, Gama-Norton L, Ruiz-Herguido C, González J, López-Bigas N, Menendez P, Dzierzak E, Espinosa L, Bigas A.
J Exp Med 211(12):2411-23. doi: 10.1084/jem.20131857. Epub 2014 Nov 10. 2014
8CDCA7
The MYC-associated protein CDCA7 is phosphorylated by AKT to regulate MYC-dependent apoptosis and transformation.
Gill RM, Gabor TV, Couzens AL, Scheid MP.
Mol Cell Biol 33(3):498-513. doi: 10.1128/MCB.00276-12. Epub 2012 Nov 19. 2013
9CDCA7, CDCA7L, MAOA
Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway.
Ou XM, Chen K, Shih JC.
Proc Natl Acad Sci U S A 103(29):10923-8. Epub 2006 Jul 7. 2006
10CDCA7
JPO1/CDCA7, a novel transcription factor E2F1-induced protein, possesses intrinsic transcriptional regulator activity.
Goto Y, Hayashi R, Muramatsu T, Ogawa H, Eguchi I, Oshida Y, Ohtani K, Yoshida K.
Biochim Biophys Acta 1759(1-2):60-8. Epub 2006 Mar 24. 2006
11CDCA7
The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.
Osthus RC, Karim B, Prescott JE, Smith BD, McDevitt M, Huso DL, Dang CV.
Cancer Res 65(13):5620-7. 2005
12CDCA7
A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation.
Prescott JE, Osthus RC, Lee LA, Lewis BC, Shim H, Barrett JF, Guo Q, Hawkins AL, Griffin CA, Dang CV.
J Biol Chem 276(51):48276-84. 2001